Thoracic circumference: A new outcome measure in spinal muscular atrophy type 1?

被引:10
|
作者
Ropars, Juliette [1 ,2 ]
Barnerias, Christine [3 ]
Hully, Marie [3 ]
Chabaliere, Delphine [3 ]
Peudenier, Sylviane [1 ]
Barzic, Audrey [1 ]
Cros, Pierrick [1 ]
Desguerre, Isabelle [3 ]
机构
[1] CHRU Brest, Serv Pediat, 2 Ave Foch, F-29609 Brest, France
[2] INSERM, Lab Traitement Informat Med, U1101, Brest, France
[3] Hop Necker Enfants Malad, AP HP, Paris, France
关键词
Spinal muscular atrophy; Neuromuscular disorder; Outcome measure; Respiratory function; Disease progression; SHAM CONTROL; SMA; INFANTS; CARE; NUSINERSEN; CONSENSUS; SURVIVAL;
D O I
10.1016/j.nmd.2019.03.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Since respiratory insufficiency is the first cause of morbidity and mortality in spinal muscular atrophy type 1 (SMA 1), specific respiratory outcome measures are needed to evaluate changes and assess innovative therapies. In this study, thoracic circumference (TC) was used as a proxy for chest growth and an indirect measurement of respiratory function. The anthropometric parameters including TC and head circumference (HC) were evaluated from birth to 13 months in 19 infants with SMA 1 and 124 control infants. TC was significantly decreased in the SMA 1 group from the first weeks of life. The control group TC/HC ratio =1 ( 0.04), and was not found to be associated with age. By contrast, it decreased with time in all infants with SMA 1 and those with a TC/HC ratio <0.85 died within 3 months. TC is a simple measurement that provided an index of chest growth and was used as evidence of early, progressive respiratory failure and under-development of the rib-cage in SMA 1. The TC/HC ratio decreased in all patients over time, reflecting the progression of the disease suggesting that TC/HC ratio could be a new measure for SMA 1 for measuring disease severity and prognosis. (C) 2019 Elsevier B.Y. All rights reserved.
引用
收藏
页码:415 / 421
页数:7
相关论文
共 50 条
  • [11] Genetic therapies for spinal muscular atrophy type 1
    Aartsma-Rus, Annemieke
    LANCET NEUROLOGY, 2018, 17 (02): : 111 - 112
  • [12] General movements in spinal muscular atrophy type 1
    Kahraman, Aysu
    Mutlu, Akmer
    Livanelioglu, Ayse
    PHYSIOTHERAPY THEORY AND PRACTICE, 2024, 40 (06) : 1249 - 1255
  • [13] Spinal muscular atrophy type 1 quality of life
    Bach, JR
    Vega, J
    Majors, J
    Friedman, A
    AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION, 2003, 82 (02) : 137 - 142
  • [14] CHILD WITH SPINAL MUSCULAR ATROPHY TYPE 1 AND POLYNEUROPATHY
    Leiva Pemberthy, Luz Miriam
    Espinosa, Katalina
    Eugenia Zuluaga, Maria
    MUSCLE & NERVE, 2021, 64 : S42 - S42
  • [15] SPINAL MUSCULAR ATROPHY TYPE 1: ESTIMATION OF SURVIVAL
    Ribero, Aponte, V
    Sutherland, C. S.
    Gorni, K.
    Mitchell, S.
    Batson, S.
    VALUE IN HEALTH, 2020, 23 : S636 - S637
  • [16] Survival of Patients With Spinal Muscular Atrophy Type 1
    Gregoretti, Cesare
    Ottonello, Giancarlo
    Testa, Maria Beatrice Chiarini
    Mastella, Chiara
    Rava, Lucilla
    Bignamini, Elisabetta
    Veljkovic, Aleksandar
    Cutrera, Renato
    PEDIATRICS, 2013, 131 (05) : E1509 - E1514
  • [17] Spinal muscular atrophy type 1: Management and outcomes
    Bach, JR
    Baird, JS
    Plosky, D
    Navado, J
    Weaver, B
    PEDIATRIC PULMONOLOGY, 2002, 34 (01) : 16 - 22
  • [18] Severe spinal muscular atrophy type 1 in the UK
    Mellis, Craig
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2011, 47 (08) : 563 - 563
  • [19] Choosing Life with Spinal Muscular Atrophy Type 1
    Lavie, Moran
    Nisnkorn, Hodaya
    Sagi, Liora
    Amirav, Israel
    ADVANCES IN THERAPY, 2020, 37 (05) : 1708 - 1713
  • [20] Defining outcome measures for clinical trials in spinal muscular atrophy type 1: preliminary results
    Finkel, RS
    Bonnemann, CG
    Weiner, DJ
    Mayer, OH
    Panitch, HB
    McDonough, JM
    Glanzman, AM
    Flickinger, JM
    Medne, L
    Schadt, KA
    Kolb, SJ
    Dreyfuss, G
    NEUROMUSCULAR DISORDERS, 2005, 15 (9-10) : 726 - 726